Kopran Limited Share Price

Equities

KOPRAN

INE082A01010

Pharmaceuticals

Market Closed - Bombay S.E. 03:55:07 26/04/2024 pm IST 5-day change 1st Jan Change
254.9 INR -1.96% Intraday chart for Kopran Limited -0.97% +5.59%
Sales 2022 4.78B 57.27M Sales 2023 5.51B 66.09M Capitalization 5.32B 63.87M
Net income 2022 610M 7.32M Net income 2023 272M 3.26M EV / Sales 2022 2.99 x
Net Debt 2022 687M 8.24M Net Debt 2023 678M 8.14M EV / Sales 2023 1.09 x
P/E ratio 2022
20.4 x
P/E ratio 2023
19.6 x
Employees 902
Yield 2022
1.07%
Yield 2023
2.72%
Free-Float 50.67%
More Fundamentals * Assessed data
Dynamic Chart
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Kopran Limited Announces Renewal of Gmp Compliance Certificate by Medicines & Healthcare Products Regulatory Agency of United Kingdom (Mhra - Uk) CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Revises Outlook to Negative MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Kopran Limited Recommends Dividend for the Year Ended March 31, 2023 CI
Kopran Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Crisil Keeps BBB+ Rating on Kopran's Bank Loans; Outlook Stable MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Kopran Limited Recommends Dividend for the Financial Year 2021-2022 CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Kopran Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
More news
1 day-1.96%
1 week-0.97%
Current month-1.35%
1 month+2.64%
3 months-0.33%
6 months+28.06%
Current year+5.59%
More quotes
1 week
253.05
Extreme 253.05
270.15
1 month
245.75
Extreme 245.75
292.00
Current year
205.60
Extreme 205.6
292.40
1 year
140.00
Extreme 140
292.40
3 years
96.00
Extreme 96
369.35
5 years
16.15
Extreme 16.15
369.35
10 years
16.15
Extreme 16.15
369.35
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 29/14/29
Compliance Officer - 28/14/28
Members of the board TitleAgeSince
Director/Board Member 68 08/19/08
Chairman 82 03/05/03
Director/Board Member 69 11/77/11
More insiders
Date Price Change Volume
26/24/26 254.9 -1.96% 30,186
25/24/25 260 -0.95% 11,244
24/24/24 262.5 +0.56% 21,167
23/24/23 261 +0.35% 30,530
22/24/22 260.2 +1.07% 21,410

Delayed Quote Bombay S.E., April 26, 2024 at 03:55 pm IST

More quotes
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
More about the company
  1. Stock Market
  2. Equities
  3. KOPRAN Stock